Therefore inhibitors of CD91, which interfere ligand binding, such as the receptor-associated protein (RAP), suramin, α2-macroglobulin, and lactoferrin27 would be useful for investigating the association of exosomal CD91 and lung cancer. Here, LRPAP1 is linked to lung cancer.